{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:07:40Z","timestamp":1793660860932,"version":"4.5.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virological Methods"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.jviromet.2019.04.017","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T12:45:44Z","timestamp":1555505144000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Screening of novel drugs for inhibiting hepatitis E virus replication"],"prefix":"10.1016","volume":"270","author":[{"given":"Takashi","family":"Nishiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7672-9100","authenticated-orcid":false,"given":"Tominari","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suljid","family":"Jirintai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6153-6250","authenticated-orcid":false,"given":"Isao","family":"Kii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Putu","family":"Prathiwi Primadharsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0827-0964","authenticated-orcid":false,"given":"Hiroaki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviromet.2019.04.017_bib0005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/cid\/ciu742","article-title":"Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse","volume":"60","author":"Abravanel","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0010","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.transproceed.2015.09.070","article-title":"Cytomegalovirus infection and rates of antiviral resistance following intestinal and multivisceral transplantation","volume":"48","author":"Ambrose","year":"2016","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0015","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.1371\/journal.pone.0000571","article-title":"A highly sensitive assay for monitoring the secretory pathway and ER stress","volume":"2","author":"Badr","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.jviromet.2019.04.017_bib0020","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1310\/hpj4905-466","article-title":"Sofosbuvir","volume":"49","author":"Cada","year":"2014","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics8010006","article-title":"Development of liposomal ciprofloxacin to treat lung infections","volume":"8","author":"Cipolla","year":"2016","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jviromet.2019.04.017_bib0030","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/82191","article-title":"The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen","volume":"6","author":"Crotty","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0035","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.gastro.2015.09.011","article-title":"Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin","volume":"150","author":"Dao Thi","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jviromet.2019.04.017_bib0040","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/icb.2012.9","article-title":"The interferons and their receptors-distribution and regulation","volume":"90","author":"de Weerd","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0045","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/AAC.01795-13","article-title":"Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon","volume":"58","author":"Debing","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0050","first-page":"1203","article-title":"A rat model for hepatitis E virus","volume":"9","author":"Debing","year":"2016","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0055","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1053\/j.gastro.2016.05.060","article-title":"Sofosbuvir and daclatasvir anti-viral therapy fails to clear HEV viremia and restore reactive T cells in a HEV\/HCV co-infected liver transplant recipient","volume":"152","author":"Donnelly","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jviromet.2019.04.017_bib0060","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijpharm.2009.11.033","article-title":"Liposomes as delivery systems for antibiotics","volume":"387","author":"Drulis-Kawa","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0065","series-title":"Fields Virol.","first-page":"2242","article-title":"Hepatitis E virus","author":"Emerson","year":"2013"},{"key":"10.1016\/j.jviromet.2019.04.017_bib0070","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1038\/s41598-018-22620-2","article-title":"Antiviral effect of ribavirin against HCV associated with increased frequency of G-to-A and C-to-U transitions in infectious cell culture model","volume":"8","author":"Galli","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0075","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.1128\/JVI.00046-06","article-title":"A bicistronic subgenomic mRNA encodes both the ORF2 and ORF3 proteins of hepatitis E virus","volume":"80","author":"Graff","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0080","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.antiviral.2017.06.005","article-title":"Identification of KX2-391 as an inhibitor of HBV transcription by a recombinant HBV-based screening assay","volume":"144","author":"Harada","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0085","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3389\/fimmu.2017.01707","article-title":"Interferon lambda genetics and biology in regulation of viral control","volume":"8","author":"Hemann","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0033-1338110","article-title":"Molecular virology of hepatitis E virus","volume":"33","author":"Holla","year":"2013","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0095","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJMra1204512","article-title":"Hepatitis E","volume":"367","author":"Hoofnagle","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0100","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1128\/AAC.02094-13","article-title":"Novel cell-based hepatitis C virus infection assay for quantitative high-throughput screening of anti-hepatitis C virus compounds","volume":"58","author":"Hu","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0105","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1128\/CMR.00057-13","article-title":"Hepatitis E virus infection","volume":"27","author":"Kamar","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0110","first-page":"4343","article-title":"Studies on the interference of ganciclovir to HCV liver fibrosis","volume":"20","author":"Li","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.virusres.2008.06.005","article-title":"Mutational events during the primary propagation and consecutive passages of hepatitis E virus strain JE03-1760F in cell culture","volume":"137","author":"Lorenzo","year":"2008","journal-title":"Virus Res."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-0033-1338113","article-title":"Zoonotic and foodborne transmission of hepatitis E virus","volume":"33","author":"Meng","year":"2013","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0125","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1086\/421491","article-title":"US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax","volume":"39","author":"Meyerhoff","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0130","doi-asserted-by":"crossref","first-page":"169","DOI":"10.12659\/AOT.892076","article-title":"Severe cytomegalovirus infection in a second kidney transplant recipient treated with ganciclovir, leflunomide, and immunoglobulins, with complications including seizures, acute HCV infection, drug-induced pancytopenia, diabetes, cholangitis, and multi-or","volume":"20","author":"Miszewska-Szyszkowska","year":"2015","journal-title":"Ann. Transplant."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0135","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3390\/molecules21040268","article-title":"The current case of quinolones: synthetic approaches and antibacterial activity","volume":"21","author":"Naeem","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.jviromet.2019.04.017_bib0140","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.virusres.2016.07.011","article-title":"Analysis of adaptive mutations selected during the consecutive passages of hepatitis E virus produced from an infectious cDNA clone","volume":"223","author":"Nagashima","year":"2016","journal-title":"Virus Res."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0145","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nrgastro.2017.150","article-title":"Hepatitis E virus: advances and challenges","volume":"15","author":"Nimgaonkar","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0150","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/cas.12799","article-title":"Novel reporter system to monitor early stages of the hepatitis B virus life cycle","volume":"106","author":"Nishitsuji","year":"2015","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0155","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00535-012-0682-0","article-title":"Culture systems for hepatitis E virus","volume":"48","author":"Okamoto","year":"2013","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0160","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0168-8278(96)80113-9","article-title":"Side effects of high-dose interferon therapy for chronic hepatitis C","volume":"25","author":"Okanoue","year":"1996","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0165","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1099\/jgv.0.000940","article-title":"ICTV virus taxonomy profile: hepeviridae","volume":"98","author":"Purdy","year":"2017","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0170","doi-asserted-by":"crossref","DOI":"10.1007\/s00705-017-3444-8","article-title":"Nucleoside analogue 2\u2019-C-methylcytidine inhibits hepatitis E virus replication but antagonizes ribavirin","author":"Qu","year":"2017","journal-title":"Arch. Virol."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0175","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1128\/JVI.00146-12","article-title":"Adaptation of a genotype 3 hepatitis E virus to efficient growth in cell culture depends on an inserted human gene segment acquired by recombination","volume":"86","author":"Shukla","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0180","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/FTD.0b013e318205f892","article-title":"Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrations","volume":"33","author":"Slavenburg","year":"2011","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0185","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a \u03b2-d-2\u2019-deoxy-2\u2019-\u03b1-fluoro-2\u2019-\u03b2-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0190","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4254\/wjh.v8.i12.557","article-title":"Antiviral therapy for hepatitis C: has anything changed for pregnant\/lactating women?","volume":"8","author":"Spera","year":"2016","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0195","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00705-008-0045-6","article-title":"Production of monoclonal antibodies against hepatitis E virus capsid protein and evaluation of their neutralizing activity in a cell culture system","volume":"153","author":"Takahashi","year":"2008","journal-title":"Arch. Virol."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0200","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0042-6822(91)90760-9","article-title":"Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome","volume":"185","author":"Tam","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.jviromet.2019.04.017_bib0205","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1099\/vir.0.82535-0","article-title":"Development and evaluation of an efficient cell-culture system for Hepatitis E virus","volume":"88","author":"Tanaka","year":"2007","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0210","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ymthe.2004.10.016","article-title":"Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo","volume":"11","author":"Tannous","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0215","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.transproceed.2012.08.020","article-title":"Hepatitis E virus infection in a liver transplant recipient in the United States: a case report","volume":"45","author":"Te","year":"2013","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0220","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1128\/AAC.02427-15","article-title":"Antiviral activities of different interferon types and subtypes against hepatitis E virus replication","volume":"60","author":"Todt","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0225","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1136\/gutjnl-2015-311000","article-title":"In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome","volume":"65","author":"Todt","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jviromet.2019.04.017_bib0230","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jhep.2016.09.014","article-title":"Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection","volume":"66","author":"van der Valk","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0235","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1053\/j.gastro.2014.02.036","article-title":"Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus","volume":"146","author":"Wang","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jviromet.2019.04.017_bib0240","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1053\/j.gastro.2016.09.061","article-title":"Distinct antiviral potency of sofosbuvir against hepatitis C and E viruses","volume":"151","author":"Wang","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jviromet.2019.04.017_bib0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-94-024-0942-0_1","article-title":"Hepatitis E virus","volume":"948","author":"Wang","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.01.005","article-title":"Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication","volume":"140","author":"Wang","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0255","article-title":"The RNA genome of hepatitis E virus robustly triggers antiviral interferon response","author":"Wang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jviromet.2019.04.017_bib0260","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0168-3659(03)00358-4","article-title":"Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection","volume":"92","author":"Wong","year":"2003","journal-title":"J. Control. Release"},{"issue":"663\u2013674","key":"10.1016\/j.jviromet.2019.04.017_bib0265","first-page":"e7","article-title":"Pan-genotype hepatitis E virus replication in stem cell-derived hepatocellular systems","volume":"154","author":"Wu","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jviromet.2019.04.017_bib0270","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/AAC.05438-11","article-title":"Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir","volume":"56","author":"Yi","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0275","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1128\/JVI.02804-15","article-title":"Distinct entry mechanisms for nonenveloped and quasi-enveloped hepatitis E viruses","volume":"90","author":"Yin","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006417","article-title":"Hepatitis E virus persists in the presence of a type III interferon response","volume":"13","author":"Yin","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jviromet.2019.04.017_bib0285","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3389\/fimmu.2017.01661","article-title":"Interferon (IFN)-\u03bb takes the helm: immunomodulatory roles of type III IFNs","volume":"8","author":"Zanoni","year":"2017","journal-title":"Front. Immunol."}],"container-title":["Journal of Virological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093418302933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093418302933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T10:51:05Z","timestamp":1759056665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166093418302933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":57,"alternative-id":["S0166093418302933"],"URL":"https:\/\/doi.org\/10.1016\/j.jviromet.2019.04.017","relation":{},"ISSN":["0166-0934"],"issn-type":[{"value":"0166-0934","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening of novel drugs for inhibiting hepatitis E virus replication","name":"articletitle","label":"Article Title"},{"value":"Journal of Virological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jviromet.2019.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}